Classement en actions
#32729
NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering... NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering advanced therapies for oncology. Its innovative product pipeline is underpinned by a proprietary ProTide technology platform. Among its key drug candidates, Acelarin is progressing through multiple clinical evaluations: a Phase I study for advanced solid tumors, Phase Ib trials for both recurrent ovarian cancer and biliary tract cancer, a Phase II trial targeting platinum-resistant ovarian cancer, and a pivotal Phase III trial for pancreatic cancer. NuCana is also developing NUC-3373, a ProTide derivative of 5-fluorouracil’s active anti-cancer metabolite. This compound is currently in a Phase I study for advanced solid tumors and a Phase Ib/2 trial for advanced colorectal cancer. Additionally, NUC-7738, a nucleoside analog, is undergoing Phase 1/2 clinical assessment for both advanced solid and hematological malignancies. To support its ProTide technology development, the company maintains research, collaboration, and licensing agreements with Cardiff University and University College Cardiff Consultants Ltd., covering the design, synthesis, characterization, and assessment of these compounds. Further collaborative and licensing arrangements are in place with Cardiff ProTides Ltd. Established in 1997, the company operated as NuCana BioMed Limited before rebranding to NuCana plc in August 2017. Its corporate headquarters are located in Edinburgh, United Kingdom.
Capitalisation boursière
$9.29M
Changement (1 jour)
-3.77%
Changement (1 an)
-58.98%
Échange NuCana plc (NCNA)
Le prix NCNA avec la capitalisation boursière de B
Capitalisation boursière de NuCana plc(NCNA)
Capitalisation boursière: $9.29M
En August 2026, NuCana plc a une capitalisation boursière de $9.29M. Cela fait de NuCana plc la 32729th entreprise la plus valorisée au monde selon nos données. La capitalisation boursière, souvent appelée market cap, correspond à la valeur totale des actions en circulation d’une entreprise cotée en bourse, et est couramment utilisée pour évaluer sa valeur.
Historique de la capitalisation boursière de NuCana plc du 2017 au 2026
NCNA par rapport au top 5 des plus populaires stocks
| Prix pour NCNA |
|
L’actif B |
La capitalisation boursière de B |
Résultats |
|
|
|
|
$5.466T
|
+58,832,468.54%
|
|
|
|
|
$4.476T
|
+48,183,737.42%
|
|
|
|
|
$4.143T
|
+44,597,013.43%
|
|
|
|
|
$3.562T
|
+38,342,226.75%
|
|
|
|
|
$2.794T
|
+30,073,827.57%
|
